{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/luts-in-men/prescribing-information/5-alpha-reductase-inhibitors/","result":{"pageContext":{"chapter":{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors","depth":2,"htmlHeader":"<!-- begin field 83626d22-9084-429f-8e5f-e9b138531c5c --><h2>5-alpha reductase inhibitors</h2><!-- end field 83626d22-9084-429f-8e5f-e9b138531c5c -->","summary":"","htmlStringContent":"<!-- begin item f21da281-0e09-48b3-9a04-e4d9895d4568 --><!-- end item f21da281-0e09-48b3-9a04-e4d9895d4568 -->","topic":{"id":"fdcce69d-578e-5994-a7c2-84be40932dd8","topicId":"a7bf3f2d-1d9e-47c0-9dd3-26731c4d092b","topicName":"LUTS in men","slug":"luts-in-men","lastRevised":"Last revised in March 2019","chapters":[{"id":"149361eb-636f-59a5-a2e2-b067d629a065","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c7972342-637c-56a9-8783-c1e8314e7fd1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7105be47-f38b-5335-b14d-69db43326579","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes"},{"id":"776566d2-009e-5ebd-ac21-e5605029213a","slug":"update","fullItemName":"Update"}]},{"id":"4c1332b1-3f4f-530f-bb70-d627804caa79","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d434ba09-30c6-5bfc-bb6f-87e952a1b33a","slug":"goals","fullItemName":"Goals"},{"id":"702b01d3-71e8-5daf-a985-3935596391f5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0aef110d-14b4-5ae2-9da0-a07cc4aef9ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fcf6ae7-162e-5b90-84fb-2a79f82d420e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1c91c138-4e44-571e-8ac0-8e62f8dca310","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4fe99a13-4e80-5c28-b091-216c8a8d7f82","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3a98397f-2bc4-5e01-90d6-03d6fbe400c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d41a85e2-c1cb-5198-afc7-7c4fbe28ae24","slug":"definitions","fullItemName":"Definitions"},{"id":"fd0f4942-31d6-517a-a10b-d341e34a2504","slug":"causes-of-luts","fullItemName":"Causes of LUTS"},{"id":"3af3e2a4-26b3-5a77-9e8b-3d393388e624","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c6eecc6-b753-5918-adae-dc2d864d88fa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1432aa0-7841-5eec-85c4-e344d4629bd9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8874a841-31e1-5356-a3f6-7bff9c28c693","slug":"assessment","fullItemName":"Assessment"},{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations"}]},{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d790431-a0c8-5ca1-8143-be639ea2ec02","slug":"voiding-symptoms","fullItemName":"Scenario: Voiding symptoms"},{"id":"b1451e1b-3776-5aa0-94b0-79be5fb01831","slug":"overactive-bladder","fullItemName":"Scenario: Overactive bladder"},{"id":"f4818005-dc3a-52b2-ac5d-d14f0d6ac0db","slug":"nocturnal-polyuria","fullItemName":"Scenario: Nocturnal polyuria"},{"id":"fb3acb54-4d76-5aad-ab1c-7b0b3d9443a3","slug":"stress-urinary-incontinence","fullItemName":"Scenario: Stress urinary incontinence"},{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention"},{"id":"0a3e83b8-a00f-520f-b21f-9ef6cc6440e7","slug":"post-micturition-dribble","fullItemName":"Scenario: Post-micturition dribble"}]},{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors"},{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron"},{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide"},{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin"}]},{"id":"dca797b5-427f-5ed5-94e4-3ad565f628a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e289c42-8089-5739-9683-20c374967578","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"07accac1-c375-54a3-92cc-d2cd8a2bb914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c05a5332-4c79-595e-b066-09dcd9841073","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e5cf2cc-d3d4-5d7d-82a7-3dd1ae3c65d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ea76bd-52d3-5c5a-8d1f-f574eec081bd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"38a45d79-a74f-5ca9-a844-f16ea2c0ab75","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b3152db-f873-5814-b35f-54711f247dff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d89afceb-5b5d-590f-8b50-da1bdf22824a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0cbd68b8-4f8d-4e99-a554-8477e76ae340 --><h3>What are the contraindications and cautions for 5-alpha reductase inhibitors?</h3><!-- end field 0cbd68b8-4f8d-4e99-a554-8477e76ae340 -->","summary":"","htmlStringContent":"<!-- begin item e6fd2241-dd73-4602-a5c6-61f2767b7433 --><!-- begin field 5f55b19d-7e9d-4dd6-b741-7098bb67dd74 --><ul><li><strong>Dutasteride</strong><ul><li>Do not prescribe dutasteride to people with severe liver disease.</li><li>Prescribe dutasteride with caution to people with mild-to-moderate liver disease — monitor for adverse effects and deterioration of liver disease.</li></ul></li><li><strong>Finasteride</strong><ul><li>To avoid obstructive complications it is important that people with large residual urine and/or heavily decreased urinary flow are carefully controlled. The possibility of surgery should be an option.</li><li>There are no data on finasteride in people with liver disease. However, a reasonable approach would be to use it in the same way as dutasteride as both drugs are eliminated mainly by hepatic metabolism.</li></ul></li><li><strong>Finasteride and dutasteride can both be absorbed through the skin and are excreted in semen.</strong><ul><li>Advise the man:<ul><li>That women should not handle crushed or broken tablets of finasteride, or leaking capsules of dutasteride, if they are pregnant or may be pregnant.</li><li>To use a condom if his sexual partner is pregnant or likely to become pregnant.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field 5f55b19d-7e9d-4dd6-b741-7098bb67dd74 --><!-- end item e6fd2241-dd73-4602-a5c6-61f2767b7433 -->","subChapters":[]},{"id":"2e43edbf-798b-5342-84d1-6d4d25cb375b","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field c3228753-d5d9-4ff6-b189-d26fec4c18d9 --><h3>What dose of 5-alpha reductase inhibitor should I use?</h3><!-- end field c3228753-d5d9-4ff6-b189-d26fec4c18d9 -->","summary":"","htmlStringContent":"<!-- begin item 059459de-e39a-42db-86f4-68c733119843 --><!-- begin field a182edff-2e9a-4ac8-9791-e164dcb6b092 --><ul><li><strong>The recommended doses are:</strong><ul><li>Finasteride — 5 mg once a day.</li><li>Dutasteride — 500 micrograms once a day.</li></ul></li><li>No dose titration is needed. However, both finasteride and dutasteride may need to be given for up to 6 months before a response is seen.</li><li>Use a validated scoring system (such as the <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/diagnosis/assessment/#international-prostate-symptom-score-ipss\">International Prostate Symptom Score</a> [IPSS] to assess and document the person's response to treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">NICE, 2015</a>].</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field a182edff-2e9a-4ac8-9791-e164dcb6b092 --><!-- end item 059459de-e39a-42db-86f4-68c733119843 -->","subChapters":[]},{"id":"dbdfc04b-55bc-5f31-b774-2be10ec83d04","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8bfc49ef-5902-4f64-92db-0ec0ef6bf2ea --><h3>What are the adverse effects of 5-alpha reductase inhibitors?</h3><!-- end field 8bfc49ef-5902-4f64-92db-0ec0ef6bf2ea -->","summary":"","htmlStringContent":"<!-- begin item 4bb039ac-4f0d-4702-85c1-feab47856fc2 --><!-- begin field 7e8ee7ab-8d04-40d9-b721-38ee17e25b2c --><ul><li><strong>5-alpha reductase inhibitors (dutasteride and finasteride) are generally well tolerated. </strong>Fewer than one in 10 men experience adverse effects (such as sexual dysfunction [decreased libido, ejaculation disorder, and impotence] and breast tenderness) in the first year of use.<ul><li>Advise the man:<ul><li>That sexual dysfunction tends to improve with duration of treatment.</li><li>To promptly report any changes in their breast tissue (such as lumps, pain, or nipple discharge) as cases of breast cancer have (rarely) been reported.</li></ul></li></ul></li><li><strong>Other adverse effects of dutasteride include:</strong><ul><li>Uncommon — alopecia and hypertrichosis.</li><li>Frequency not known — angioedema, depression, hypersensitivity and skin reactions, localized oedema, and testicular disorders.</li></ul></li><li><strong>Other adverse effects of finasteride include:</strong><ul><li>Uncommon — depression, skin reactions, and suicidal thoughts.<ul><li>The Medicines and Healthcare Products Regulatory Agency (MHRA) has received reports of depression and, in rare cases, suicidal thoughts in men taking finasteride (Propecia<sup>®</sup>) for male pattern hair loss; depression is also associated with Proscar<sup>®</sup> for benign prostatic hyperplasia.</li><li>Advise men taking to stop finasteride immediately and inform a healthcare professional if they develop depression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">MHRA, 2017</a>].</li></ul></li><li>Frequency not known —<strong> </strong>angioedema, male infertility, palpitations, and testicular pain.</li></ul></li><li><strong>After 6 months of treatment, 5-alpha reductase inhibitors can cause a decrease in mean serum prostate specific antigen (PSA) levels by approximately 50%.</strong><ul><li>Men being treated with dutasteride or finasteride should have a new PSA baseline established after 6 months of treatment. It is recommended to monitor PSA values regularly thereafter. Any confirmed increase from lowest PSA level while on a 5-alpha reductase inhibitor may signal the presence of prostate cancer or noncompliance to treatment and should be carefully evaluated, even if those values are still within the normal range for people not taking a 5-alpha reductase inhibitor. In the interpretation of a PSA value for a man taking a 5-alpha reductase inhibitor, previous PSA values should be sought for comparison.</li><li>Digital rectal examination, and other evaluations for prostate cancer, must be performed prior to initiating a 5-alpha reductase inhibitor and periodically thereafter.</li><li>Total serum PSA levels return to baseline within 6 months of discontinuing treatment. The ratio of free to total PSA remains constant even under the influence of 5-alpha reductase inhibitors. If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men undergoing 5-alpha reductase inhibitor treatment, no adjustment to its value appears necessary.</li><li>Treatment with dutasteride does not interfere with the use of PSA as a tool to assist in the diagnosis of prostate cancer after a new baseline has been established.</li></ul></li><li><strong>Finasteride and dutasteride can both be absorbed through the skin and are excreted in semen.</strong><ul><li>Advise the man:<ul><li>That women should not handle crushed or broken tablets of finasteride, or leaking capsules of dutasteride, if they are pregnant or may be pregnant.</li><li>To use a condom if his sexual partner is pregnant or likely to become pregnant.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field 7e8ee7ab-8d04-40d9-b721-38ee17e25b2c --><!-- end item 4bb039ac-4f0d-4702-85c1-feab47856fc2 -->","subChapters":[]},{"id":"ea3168a1-bb6a-54ea-b711-b36946ada99b","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field bb25f05f-2fad-4d40-b38f-609efa67cf2f --><h3>What are the key drug interactions of 5-alpha reductase inhibitors?</h3><!-- end field bb25f05f-2fad-4d40-b38f-609efa67cf2f -->","summary":"","htmlStringContent":"<!-- begin item 607ac345-7d27-40bd-adb1-6f729f4d3a1c --><!-- begin field 4cccb164-0e20-4068-8f88-e585ea1a2a4e --><ul><li><strong>Dutasteride </strong>is metabolized by cytochrome P450 3A4 (CYP3A4).<ul><li>Consider reducing the dosing frequency of dutasteride if adverse effects occur during long-term concurrent treatment with potent CYP3A4 inhibitors (such as itraconazole, ritonavir, and clarithromycin).</li></ul></li><li><strong>Finasteride </strong>has no clinically important drug interactions.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field 4cccb164-0e20-4068-8f88-e585ea1a2a4e --><!-- end item 607ac345-7d27-40bd-adb1-6f729f4d3a1c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}